WO2003087087A3 - Heterocyclic compounds and their use as modulators of p38 map kinase - Google Patents

Heterocyclic compounds and their use as modulators of p38 map kinase Download PDF

Info

Publication number
WO2003087087A3
WO2003087087A3 PCT/GB2003/001507 GB0301507W WO03087087A3 WO 2003087087 A3 WO2003087087 A3 WO 2003087087A3 GB 0301507 W GB0301507 W GB 0301507W WO 03087087 A3 WO03087087 A3 WO 03087087A3
Authority
WO
WIPO (PCT)
Prior art keywords
group
hydrogen
hydrocarbyl
halogen
map kinase
Prior art date
Application number
PCT/GB2003/001507
Other languages
French (fr)
Other versions
WO2003087087A2 (en
Inventor
Martyn Frederickson
Adrian Liam Gill
Alessandro Padova
Miles Stuart Congreve
Original Assignee
Astex Technology Ltd
Martyn Frederickson
Adrian Liam Gill
Alessandro Padova
Miles Stuart Congreve
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0208248A external-priority patent/GB0208248D0/en
Priority claimed from GB0215180A external-priority patent/GB0215180D0/en
Application filed by Astex Technology Ltd, Martyn Frederickson, Adrian Liam Gill, Alessandro Padova, Miles Stuart Congreve filed Critical Astex Technology Ltd
Priority to JP2003584043A priority Critical patent/JP2005526831A/en
Priority to EP03720680A priority patent/EP1495016A2/en
Priority to AU2003224257A priority patent/AU2003224257A1/en
Publication of WO2003087087A2 publication Critical patent/WO2003087087A2/en
Publication of WO2003087087A3 publication Critical patent/WO2003087087A3/en
Priority to US10/962,085 priority patent/US20050124620A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • AIDS & HIV (AREA)
  • Hospice & Palliative Care (AREA)
  • Transplantation (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention provides a compound for use in the prophylaxis or treatment of a disease state or condition mediated by a p38 MAP kinase such as rheumatoid arthritis and osteoarthritis; the compound being of the general formula (I): wherein U, T, V and W are each a nitrogen atom or a group CR4 provided that no more than three of U, T, V and W are nitrogen atoms; R0 is hydrogen, C1-4 hydrocarbyl, halogen or a group -A-R3; R1 is hydrogen, C1-4 hydrocarbyl or a group -A-R3; provided that only one of R0 and R1 is a group -A-R3; R2 is hydrogen, C1-4 hydrocarbyl or halogen; A is a carbon- or heteroatom-containing linker group having a linking chain length of one or two atoms; R3 is a monocyclic or bicyclic heteroaryl group containing from five to twelve ring members; each group R4 is independently selected from hydrogen, hydroxy, halogen, nitro, cyano, a monocyclic heterocyclic group having up to seven ring members, a group N(R5)2, a group C(O)N(R6)2, a group S02N(R6)2, a group Ra-Rb and a group Y; provided that no more than one group Y is present;
PCT/GB2003/001507 2002-04-09 2003-04-08 Heterocyclic compounds and their use as modulators of p38 map kinase WO2003087087A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
JP2003584043A JP2005526831A (en) 2002-04-09 2003-04-08 Pharmaceutical compounds
EP03720680A EP1495016A2 (en) 2002-04-09 2003-04-08 Heterocyclic compounds and their use as modulators of p38 map kinase
AU2003224257A AU2003224257A1 (en) 2002-04-09 2003-04-08 Heterocyclic compounds and their use as modulators of p38 map kinase
US10/962,085 US20050124620A1 (en) 2002-04-09 2004-10-08 Pharmaceutical compounds

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB0208248.5 2002-04-09
GB0208248A GB0208248D0 (en) 2002-04-09 2002-04-09 Pharmaceutical compounds
GB0215180.1 2002-06-29
GB0215180A GB0215180D0 (en) 2002-06-29 2002-06-29 Pharmaceutical compounds

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US10/962,085 Continuation US20050124620A1 (en) 2002-04-09 2004-10-08 Pharmaceutical compounds

Publications (2)

Publication Number Publication Date
WO2003087087A2 WO2003087087A2 (en) 2003-10-23
WO2003087087A3 true WO2003087087A3 (en) 2003-12-18

Family

ID=29252442

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2003/001507 WO2003087087A2 (en) 2002-04-09 2003-04-08 Heterocyclic compounds and their use as modulators of p38 map kinase

Country Status (4)

Country Link
EP (1) EP1495016A2 (en)
JP (1) JP2005526831A (en)
AU (1) AU2003224257A1 (en)
WO (1) WO2003087087A2 (en)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8865735B2 (en) 2011-02-21 2014-10-21 Hoffman-La Roche Inc. Solid forms of a pharmaceutically active substance
US9096593B2 (en) 2009-11-06 2015-08-04 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
US9150570B2 (en) 2012-05-31 2015-10-06 Plexxikon Inc. Synthesis of heterocyclic compounds
US9169250B2 (en) 2006-11-22 2015-10-27 Plexxikon Inc. Compounds modulating c-fms and/or c-kit activity and uses therefor
US9447089B2 (en) 2009-04-03 2016-09-20 Plexxikon Inc. Compositions and uses thereof
US9469640B2 (en) 2007-07-17 2016-10-18 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7291639B2 (en) 2001-06-20 2007-11-06 Wyeth Aryloxy-acetic acid compounds useful as inhibitors of plasminogen activator inhibitor-1 (PAI-1)
JP4399253B2 (en) 2001-06-20 2010-01-13 ワイス Substituted indoleic acid derivatives as inhibitors of plasminogen activator inhibitor-1 (PAI-1)
JP2006505571A (en) * 2002-10-15 2006-02-16 リゲル ファーマシューテイカルズ、インコーポレイテッド Substituted indoles and their use as HCV inhibitors
WO2004052855A2 (en) 2002-12-10 2004-06-24 Wyeth Substituted 3-carbonyl-1h-indol-1-yl acetic acid derivatives as inhibitors of plasminogen activator inhibitor-1 (pai-1)
DK1569901T3 (en) 2002-12-10 2009-02-16 Wyeth Corp Aryl, aryloxy and alkoxy-substituted 1H-indol-3-yl-glyoxylic acid derivatives as inhibitors of plasminogen activator inhibitor-1 (PAI-1)
UA80453C2 (en) 2002-12-10 2007-09-25 Derivatives of substituted dyhydropyranoindol-3,4-dion as inhibitors of plasminogen activator inhibitor-1 (pai-1)
CA2509222A1 (en) 2002-12-10 2004-06-24 Wyeth Substituted indole oxo-acetyl amino acetic acid derivatives as inhibitors of plasminogen activator inhibitor-1 (pai-1)
MXPA05012377A (en) 2003-05-15 2006-05-25 Arqule Inc Imidazothiazoles and imidazoxazole derivatives as inhibitors of p38.
US7411083B2 (en) 2003-09-25 2008-08-12 Wyeth Substituted acetic acid derivatives
GB0400895D0 (en) * 2004-01-15 2004-02-18 Smithkline Beecham Corp Chemical compounds
PT1753764E (en) 2004-06-09 2009-01-28 Glaxo Group Ltd Pyrrolopyridine derivatives
AR050253A1 (en) 2004-06-24 2006-10-11 Smithkline Beecham Corp COMPOSITE DERIVED FROM INDAZOL CARBOXAMIDE, COMPOSITION THAT INCLUDES IT AND ITS USE FOR THE PREPARATION OF A MEDICINAL PRODUCT
US7829560B2 (en) 2004-07-08 2010-11-09 Arqule, Inc. 1,4-disubstituted naphthalenes as inhibitors of P38 MAP kinase
CA2576297C (en) 2004-08-12 2011-01-25 Pfizer Inc. Triazolopyridinylsulfanyl derivatives as p38 map kinase inhibitors
WO2006023865A1 (en) 2004-08-23 2006-03-02 Wyeth Oxazolo-naphthyl acids as plaminogen activator inhibtor type-1 (pai-1) modulators useful in the treatment of thrombosis and cardiovascular diseases
EP1809636A1 (en) 2004-10-19 2007-07-25 Arqule, Inc. Synthesis of imidazooxazole and imidazothiazole inhibitors of p38 map kinase
JP2008526988A (en) * 2005-01-14 2008-07-24 シージーアイ ファーマシューティカルズ，インコーポレーテッド 1,3-Diaryl-substituted ureas as kinase activity modulators
CA2603457A1 (en) * 2005-04-07 2006-10-19 Teijin Pharma Limited Pyrazolo[1,5-a]pyridine derivatives or pharmaceutically acceptable salts thereof
WO2007024294A2 (en) 2005-05-03 2007-03-01 Cgi Pharmaceuticals, Inc. Certain substituted ureas, as modulators of kinase activity
US8063071B2 (en) 2007-10-31 2011-11-22 GlaxoSmithKline, LLC Chemical compounds
CA2618513A1 (en) * 2005-08-11 2007-02-22 Ariad Pharmaceuticals, Inc. Unsaturated heterocyclic derivatives
JP2009504762A (en) 2005-08-17 2009-02-05 ワイス Substituted indoles and methods for their use
ES2301380B1 (en) 2006-08-09 2009-06-08 Laboratorios Almirall S.A. NEW DERIVATIVES OF 1,7-NAFTIRIDINE.
WO2008029168A2 (en) * 2006-09-08 2008-03-13 Summit Corporation Plc Treatment of duchenne muscular dystrophy
ES2320955B1 (en) 2007-03-02 2010-03-16 Laboratorios Almirall S.A. NEW DERIVATIVES OF 3 - ((1,2,4) TRIAZOLO (4,3-A) PIRIDIN-7-IL) BENZAMIDA.
AR065804A1 (en) 2007-03-23 2009-07-01 Smithkline Beecham Corp COMPOSITE OF INDOL CARBOXAMIDE, PHARMACEUTICAL COMPOSITION THAT UNDERSTANDS IT AND USE OF THIS COMPOUND TO PREPARE A MEDICINAL PRODUCT
ES2329639B1 (en) 2007-04-26 2010-09-23 Laboratorios Almirall S.A. NEW DERIVATIVES OF 4,8-DIFENILPOLIAZANAFTALENO.
EP2108641A1 (en) 2008-04-11 2009-10-14 Laboratorios Almirall, S.A. New substituted spiro[cycloalkyl-1,3'-indo]-2'(1'H)-one derivatives and their use as p38 mitogen-activated kinase inhibitors
EP2113503A1 (en) 2008-04-28 2009-11-04 Laboratorios Almirall, S.A. New substituted indolin-2-one derivatives and their use as p39 mitogen-activated kinase inhibitors
CN102089278A (en) * 2008-06-11 2011-06-08 Irm责任有限公司 Compounds and compositions useful for the treatment of malaria
US8354539B2 (en) 2009-03-10 2013-01-15 Glaxo Group Limited Indole derivatives as IKK2 inhibitors
EP2440558B1 (en) 2009-06-08 2015-04-01 Takeda Pharmaceutical Company Limited Dihydropyrrolonaphtyridinone compounds as inhibitors of jak
EP2322176A1 (en) 2009-11-11 2011-05-18 Almirall, S.A. New 7-phenyl-[1,2,4]triazolo[4,3-a]pyridin-3(2H)-one derivatives
DE102010034699A1 (en) * 2010-08-18 2012-02-23 Merck Patent Gmbh pyrimidine derivatives
AU2012214762B2 (en) 2011-02-07 2015-08-13 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
WO2012110773A1 (en) * 2011-02-17 2012-08-23 Cancer Therapeutics Crc Pty Limited Fak inhibitors
SG11201504754QA (en) 2012-12-21 2015-07-30 Plexxikon Inc Compounds and methods for kinase modulation, and indications therefor
WO2015042052A1 (en) 2013-09-17 2015-03-26 Pharmakea, Inc. Heterocyclic vinyl autotaxin inhibitor compounds
WO2015042053A1 (en) * 2013-09-17 2015-03-26 Pharmakea, Inc. Vinyl autotaxin inhibitor compounds
PL3416964T3 (en) * 2016-02-19 2021-10-18 Phoenix Molecular Designs 6-oxo-n-(1-(benzyl)-1h-pyrazol-4-yl)-6,7,8,9- tetrahydropyrido[3',2':4,5]pyrrolo[1,2-a]pyrazine-2-carboxamide derivatives as p90 ribosomal s6 kinase (rsk) inhibitors for treating cancer
WO2017151409A1 (en) 2016-02-29 2017-09-08 University Of Florida Research Foundation, Incorporated Chemotherapeutic methods
KR102247779B1 (en) * 2019-09-18 2021-05-04 한국과학기술연구원 Novel heteroaryl amide derivatives as MAO-B inhibitors and pharmaceutical compositions for preventing, ameliorating or treating neurodegenerative diseases comprising the same

Citations (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2695290A (en) * 1952-03-28 1954-11-23 Hoffmann La Roche Derivatives of indole and method for the production thereof
GB842996A (en) * 1956-06-22 1960-08-04 Irwin Neisler & Co Pyridine derivatives
US3300506A (en) * 1959-10-16 1967-01-24 Neisler Lab Inc 1-indolyl substituted-2-pyridyl-ethanes
US4496572A (en) * 1981-08-26 1985-01-29 Pfizer Inc. Benzo-fused thromboxane synthetase inhibitors
EP0471296A1 (en) * 1990-08-13 1992-02-19 Hoechst-Roussel Pharmaceuticals Incorporated 1-(Pyridinylalkyl)-1H-indoles, indolines and related analogs
JPH0543544A (en) * 1991-08-09 1993-02-23 Nisshin Flour Milling Co Ltd Indole derivative and anticancer agent resistance overcomer containing the same as active ingredient
WO1993018026A1 (en) * 1992-03-04 1993-09-16 Beecham Group Plc Indole ureas as 5-ht1c receptor antogonists
EP0733628A1 (en) * 1995-03-20 1996-09-25 Eli Lilly And Company 5-Substituted-3-(1,2,3,6-tetrahydropyridin-4-yl)- and 3-(piperidin-4-yl)-1h-indoles: new 5-ht1f agonists
WO1996039382A1 (en) * 1995-06-06 1996-12-12 Fujisawa Pharmaceutical Co., Ltd. Urea derivatives as 5-ht antagonists
WO1999043654A2 (en) * 1998-02-25 1999-09-02 Genetics Institute, Inc. Inhibitors of phospholipase enzymes
US6069156A (en) * 1995-04-10 2000-05-30 Fujisawa Pharmaceutical Co., Ltd. Indole derivatives as cGMP-PDE inhibitors
WO2000046198A1 (en) * 1999-02-05 2000-08-10 Astrazeneca Ab Anti-inflammatory indole derivatives
WO2001047922A2 (en) * 1999-12-24 2001-07-05 Aventis Pharma Limited Azaindoles

Patent Citations (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2695290A (en) * 1952-03-28 1954-11-23 Hoffmann La Roche Derivatives of indole and method for the production thereof
GB842996A (en) * 1956-06-22 1960-08-04 Irwin Neisler & Co Pyridine derivatives
US3300506A (en) * 1959-10-16 1967-01-24 Neisler Lab Inc 1-indolyl substituted-2-pyridyl-ethanes
US4496572A (en) * 1981-08-26 1985-01-29 Pfizer Inc. Benzo-fused thromboxane synthetase inhibitors
EP0471296A1 (en) * 1990-08-13 1992-02-19 Hoechst-Roussel Pharmaceuticals Incorporated 1-(Pyridinylalkyl)-1H-indoles, indolines and related analogs
JPH0543544A (en) * 1991-08-09 1993-02-23 Nisshin Flour Milling Co Ltd Indole derivative and anticancer agent resistance overcomer containing the same as active ingredient
WO1993018026A1 (en) * 1992-03-04 1993-09-16 Beecham Group Plc Indole ureas as 5-ht1c receptor antogonists
EP0733628A1 (en) * 1995-03-20 1996-09-25 Eli Lilly And Company 5-Substituted-3-(1,2,3,6-tetrahydropyridin-4-yl)- and 3-(piperidin-4-yl)-1h-indoles: new 5-ht1f agonists
US6069156A (en) * 1995-04-10 2000-05-30 Fujisawa Pharmaceutical Co., Ltd. Indole derivatives as cGMP-PDE inhibitors
WO1996039382A1 (en) * 1995-06-06 1996-12-12 Fujisawa Pharmaceutical Co., Ltd. Urea derivatives as 5-ht antagonists
WO1999043654A2 (en) * 1998-02-25 1999-09-02 Genetics Institute, Inc. Inhibitors of phospholipase enzymes
WO2000046198A1 (en) * 1999-02-05 2000-08-10 Astrazeneca Ab Anti-inflammatory indole derivatives
WO2001047922A2 (en) * 1999-12-24 2001-07-05 Aventis Pharma Limited Azaindoles

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
BIOCHEM. PHARMACOL., vol. 51, no. 2, 1996, US, pages 159 - 63 *
CHEMICAL ABSTRACTS, vol. 119, no. 27, 1993, Columbus, Ohio, US; abstract no. 180651v, page 773; XP002257894 *
CHEMICAL ABSTRACTS, vol. 124, no. 11, 1996, Columbus, Ohio, US; abstract no. 135662s, JOHN F. REINHARD JR.: "EFFECTS OF 540C91{E-3}[2-(4'-PYRIDYL)-VINYL]-INDOLE" page 148; column 1; XP002257895 *
CHEMICAL ABSTRACTS, vol. 53, no. 11, 1959, Columbus, Ohio, US; abstract no. 9462i, J.H. MIRSKY: "CNS DEPRESSANT OF SOME INDOLYL-ETHYLPYRIDINES." page 9462; XP002257897 *
CHEMICAL ABSTRACTS, vol. 70, no. 27, 1969, Columbus, Ohio, US; abstract no. 19857b, A.K.SHEINKMAN: "SYNTHESIS A. PHARMACOLOGY OF N-(PYRIDYLALKYL)-INDOLINES AND INDOLES." page 1973; column 2; XP002257896 *
J. PHARMACOL. EXPTL. THERAP., vol. 125, 1959, pages 122 - 7 *
KHIM.-FARM. ZH., vol. 2, no. 9, 1968, USSR, pages 29 - 35 *

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9169250B2 (en) 2006-11-22 2015-10-27 Plexxikon Inc. Compounds modulating c-fms and/or c-kit activity and uses therefor
US9487515B2 (en) 2006-11-22 2016-11-08 Plexxikon Inc. Compounds modulating c-fms and/or c-kit activity and uses therefor
US9469640B2 (en) 2007-07-17 2016-10-18 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
US9447089B2 (en) 2009-04-03 2016-09-20 Plexxikon Inc. Compositions and uses thereof
US9096593B2 (en) 2009-11-06 2015-08-04 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
US8865735B2 (en) 2011-02-21 2014-10-21 Hoffman-La Roche Inc. Solid forms of a pharmaceutically active substance
US9150570B2 (en) 2012-05-31 2015-10-06 Plexxikon Inc. Synthesis of heterocyclic compounds

Also Published As

Publication number Publication date
AU2003224257A8 (en) 2003-10-27
AU2003224257A1 (en) 2003-10-27
JP2005526831A (en) 2005-09-08
EP1495016A2 (en) 2005-01-12
WO2003087087A2 (en) 2003-10-23

Similar Documents

Publication Publication Date Title
WO2003087087A3 (en) Heterocyclic compounds and their use as modulators of p38 map kinase
NO20060324L (en) [1,8] Naphthyridin-2-ones and related compounds for the treatment of schizophrenia
DE60232065D1 (en) INDOL, AZAINDOL AND RELATED HETEROCYCLIC AMIDOPIPERAZINE DERIVATIVES
NO20045282L (en) Inhibitors of Jak protein kinase
NO20035583D0 (en) Imidazo` 1,2-A pyridine derivatives for prophylaxis and treatment of herpes viral infections
GB0220581D0 (en) Organic Compound
CA2339630A1 (en) Carboline derivatives as cgmp phosphodiesterase inhibitors
AR038481A1 (en) DERIVATIVES OF DIHIDROBENZODIAZEPIN-2-ONA III FOR THE TREATMENT OF NEUROLOGICAL DISORDERS
HK1069169A1 (en) Substituted tetracyclic pyrroloquinolone derivatives useful as phosphodiesterase inhibitors
NO20050525L (en) Benzimidazol-1-yl-thiophene compounds for the treatment of cancer
ATE164575T1 (en) SUBSTITUTED AROMATIC COMPOUNDS AS CAMP PHOSPHODIESTERASE AND TNF INHIBITORS
HUP0402458A2 (en) Chemokine receptor binding heterocyclic compounds with enhanced efficacy
TW200510342A (en) Chemical compounds
ATE296826T1 (en) PYRAZOLO(1,5)PYRIDINE DERIVATIVES
DK0874824T3 (en) Trisubstituted phenyl derivatives useful as PDE IV inhibitors
AU2003248978A1 (en) Fused heteroaryl derivatives for use as p38 kinase inhibitors in the treatment of i.a. rheumatoid arthristis
HUP0401950A2 (en) Pyrimidine derivatives and pharmaceutical compositions containing that compounds
NO20051695L (en) Novel spirocondensed quinazolinones and their use as phosphodiesterase inhibitors
WO2004043337A3 (en) Indole, azaindole and related heterocyclic 4-alkenyl piperidine amides
MX2007008308A (en) N- (heteroaryl) -1h-indole-2-carb0xamide derivatives and their use as vanilloid trpv1 receptor ligands.
RS20050450A (en) 2-aminocarbonyl-quinoline compounds as platelet adenosine diphosphate receptor antagonists
MY131465A (en) "novel dioxcyclobutene derivatives, processes for their preparations, and their use as angiotensin ii antagonists"
DE60014394D1 (en) AMINOBENZOPHENONE AS INHIBITORS OF IL-1BETA AND TNF-ALPHA
GB0223232D0 (en) Chemical compounds
NO20066011L (en) Mercaptoimidazoles as CCR2 Receptor Antagonists

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 10962085

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2003584043

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2003720680

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2003720680

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2003720680

Country of ref document: EP